EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer

Zhen Zhu, Yuyong Shen, Xingjun He, Ming Zhou

Frontiers in Pharmacology · 18.08.2026 · 17

DOI: 10.3389/fphar.2026.1876355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.08.2026. Verfasst von Zhen Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Castration-resistant prostate cancer (CRPC) develops through tumor-cell plasticity, androgen receptor (AR) pathway rewiring, and immune/stromal changes under therapeutic pressure. Because metastatic CRPC often responds incompletely to immunotherapy and AR-directed treatment, cell-resolved analyses may help place putative drug-response factors within their tissue context. We examined whether secretory leukocyte protease inhibitor (SLPI), an epithelial secreted factor with immunoregulatory functions, is related to epithelial-state changes and enzalutamide response.

Methods

Public single-cell RNA-sequencing data from localized prostate cancer and metastatic CRPC (GSE274229) were analyzed using Seurat-based preprocessing, cell-type annotation, UCell pathway/state scoring, CellChat ligand-receptor inference, CopyKAT malignant-cell inference, Monocle2 trajectory analysis, hdWGCNA network analysis, and TCGA-PRAD clinical association analysis. SLPI was evaluated in 22Rv1 and C4-2 prostate cancer models using stable overexpression, qRT-PCR, proliferation, colony formation, migration, AR-pathway modulation, enzalutamide dose-response, and Annexin V/PI apoptosis assays.

Results

Progression to mCRPC was accompanied by altered epithelial-immune/stromal communication and shifts in inflammatory, extracellular-matrix, growth-factor, and immune-regulatory signaling. Putative malignant epithelial populations showed reduced AR-dependency and luminal-identity scores together with increased stress-adaptation and plasticity programs. Network and clinical association analyses highlighted SLPI as a progression-related epithelial factor with outcome relevance. In vitro , SLPI expression was lower in prostate cancer cells than in RWPE-1 cells, and SLPI overexpression suppressed proliferation, migration, and clonogenic growth. AR-pathway modulation showed reciprocal changes in SLPI expression: androgen deprivation and AR knockdown increased SLPI expression, whereas DHT-mediated AR reactivation reduced SLPI expression. SLPI overexpression enhanced enzalutamide-induced growth inhibition and apoptosis in the tested cell-line models.

Conclusion

These findings place SLPI at the intersection of AR-pathway state, epithelial adaptation, immune-context changes, and enzalutamide sensitivity in CRPC. SLPI may represent a therapy-response-associated epithelial factor in prostate cancer, but further protein-level, loss-of-function, in vivo , and clinically annotated validation will be required.

Schlagwörter

Stichwörter der Autor:innen

ImmunoregulationSLPIcastration-resistant prostate cancerenzalutamideprostate cancersingle-cell RNA sequencingtherapeutic sensitivitytumor ecosystem

Autor:innen und Institutionen

  • Department of Urology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.

Zitieren

APA

Zhu, Z., Shen, Y., He, X., & Zhou, M. (2026). SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1876355

Vancouver

Zhu Z, Shen Y, He X, Zhou M. SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1876355

BibTeX
@article{Zhu2026,
  author = {Zhu, Zhen and Shen, Yuyong and He, Xingjun and Zhou, Ming},
  title = {SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1876355}
}
Kostenlos starten →